GSK Asks Senate To Rethink Patent Reform Act
The chief executive of pharmaceutical giant GlaxoSmithKline Plc has urged senators to rethink a key provision of the Patent Reform Act, according to a letter acquired by the PLI patent blog....To view the full article, register now.
Already a subscriber? Click here to view full article